NPCE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuropace Inc (NPCE) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows promising revenue growth and bullish technical indicators, the lack of significant positive catalysts, weak financial performance in terms of net income and EPS, and no strong trading signals suggest holding off on immediate investment.
The technical indicators are bullish with MACD above zero and positively contracting, RSI at 78.228 in the neutral zone, and moving averages showing a bullish trend (SMA_5 > SMA_20 > SMA_200). The pre-market price of $17.21 is above the key pivot level of $15.894, suggesting upward momentum. However, RSI nearing overbought levels warrants caution.
Revenue growth of 23.86% YoY in Q4 2025 and a gross margin increase to 77.4%. Analysts maintain a Buy rating with a price target of $19, indicating potential upside.
No recent news or significant insider, hedge fund, or political trading activity. Congress trading data is absent.
In Q4 2025, revenue increased to $26.59M (up 23.86% YoY), but net income dropped to -$2.73M (-48.02% YoY), and EPS fell to -0.08 (-55.56% YoY). Gross margin improved slightly to 77.4% (+2.64% YoY).
Analysts maintain a Buy rating with a price target of $19, reflecting confidence in the company's growth potential. H.C. Wainwright expects core revenue growth of 20%-22% in 2026.
